Nt-probnp-based screening
1 paper2 findings
- 1 lab in 1 country
- Funder: AstraZeneca
- 2 of 2 findings with company ties
- Human trial1
Outcomes
2Sodium-glucose cotransporter 2 inhibitors
upin humans1
1 study
Sodium-glucose cotransporter 2 inhibitors
upin humans1
Nt-probnp-based screening increases sodium-glucose cotransporter 2 inhibitors in humans (24% to 39%).
Human trialtype 1 or type 2 diabetes and at least 1 additional heart failure risk factorn = 354
Journal of the American College of Cardiology11 Aug 2026
Heart failure
upin humans1
1 study
Heart failure
upin humans1
Nt-probnp-based screening increases heart failure in humans (OR: 58; 95% CI: 14-236).
Human trialtype 1 or type 2 diabetes and at least 1 additional heart failure risk factor6 monthsn = 706
Journal of the American College of Cardiology11 Aug 2026
Latest
1 in 12 monthsJournal of the American College of Cardiology
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF)
Randomised trial in 706 peopleHeart failure